Our mission statement and our pledge to our investors, friends and families:
Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself.
This mission will be achieved within within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility.
Our goals are:
to become the first and the largest drug discovery company in aging and age-related diseases;
to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment;
Some of our recent publications:
Zhavoronkov A, Buzdin AA, Garazha AV, Borissov NM and Moskalev AA (2014) Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front. Genet. 5:49. doi: 10.3389/fgene.2014.00049 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/full#sthash.6HfgzBx9.dpuf
Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY and Borisov NM (2014). OncoFinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front. Genet. 5:55. doi: 10.3389/fgene.2014.00055 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00055/full#sthash.9XPxTZ3z.dpuf
Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself.
This mission will be achieved within within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility.
Our goals are:
to become the first and the largest drug discovery company in aging and age-related diseases;
to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment;
Some of our recent publications:
Zhavoronkov A, Buzdin AA, Garazha AV, Borissov NM and Moskalev AA (2014) Signaling pathway cloud regulation for in silico screening and ranking of the potential geroprotective drugs. Front. Genet. 5:49. doi: 10.3389/fgene.2014.00049 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00049/full#sthash.6HfgzBx9.dpuf
Buzdin AA, Zhavoronkov AA, Korzinkin MB, Venkova LS, Zenin AA, Smirnov PY and Borisov NM (2014). OncoFinder, a new method for the analysis of intracellular signaling pathway activation using transcriptomic data. Front. Genet. 5:55. doi: 10.3389/fgene.2014.00055 - See more at: http://journal.frontiersin.org/Journal/10.3389/fgene.2014.00055/full#sthash.9XPxTZ3z.dpuf
Location: China, Hong Kong Island, Hong Kong
Employees: 51-200
Total raised: $60M
Founded date: 2014
Investors 1
| Date | Name | Website |
| - | SoGal Vent... | sogalventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.06.2022 | Series D | $60M | - |
Mentions in press and media 22
| Date | Title | Description |
| 03.03.2026 | Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery | Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks while running entirely on private pharmaceutical infrastructure CAMBRIDGE, Mass., March 3, 2026 /PRNewswire/ -- Insilico Medicine and Liquid ... |
| 08.11.2022 | Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion | Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up to 6 targets, and additional R&D and sales milestones plus tier-based mid-single- to low double-digit royalties. New York , Nov. 8, 2022 /PRNe... |
| 16.06.2022 | Insilico Medicine appoints Dr. Feng Ren as co-CEO | Dr. Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is named co-CEO of Insilico Medicine Highlights: Insilico Medicine is a global, end-to-end, fully-integrated AI-powered biotechnology company with thre... |
| 06.06.2022 | Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory | NEW YORK, June 6, 2022 /PRNewswire/ -- Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, announced today that it has completed a $60 million Series D financing from a syndicate of glo... |
| 06.06.2022 | Insilico Medicine Raises $60M in Series D Financing | Insilico Medicine, a NYC-based clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, raised $60m in Series D financing. New investors, including a large, diversified asset management firm on the US West Coast... |
| 25.05.2022 | Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment | Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. The candidate is intended to be used for the treatment of SARS-CoV-2 and i... |
| 24.05.2022 | Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment | Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. The candidate is intended to be used for the treatment of SARS-CoV-2 and i... |
| 05.05.2022 | Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers | NEW YORK, May 5, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced that the company has nominated a preclinical candidate (... |
| 13.04.2022 | Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders | Insilico Medicine Nominates Its USP1 Small Molecule Inhibitor as a Preclinical Candidate for Tumors with Homologous Recombination Deficiency NEW YORK, April 13, 2022 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage... |
| 24.03.2022 | Insilico Medicine Announces Strategic Collaboration with EQRx to Jointly Advance AI-driven Drug Discovery, Development and Commercialization for Multiple Targets | The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient acc... |
Show more